Shared care protocol – lisdexamfetamine in children and adults
This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Update information
Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.
Current version: v2.1
Last updated: 21st July 2026
Formulary assessment – Methylphenidate 2mg/ml oral solution
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Budget impact of methylphenidate modified release tablet choice
The purpose of this bulletin is to highlight the difference in cost between bioequivalent methylphenidate modified release (MR) tablets. It considers the budget impact of MR tablet choice and shows the yearly primary care spend on all methylphenidate XL tablets, and the proportion of this spend on each of the available brands.
Solriamfetol for obstructive sleep apnoea
Overview
Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.
Solriamfetol is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). This publication reviews its efficacy and safety, and the limitations of the evidence.
Solriamfetol is also licensed to improve wakefulness and reduce EDS in adults with narcolepsy with or without cataplexy (see separate RDTC evaluation).
Solriamfetol for narcolepsy
Overview
Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.
Solriamfetol is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy with or without cataplexy. This publication reviews its efficacy and safety, and the limitations of the evidence.
Solriamfetol is also licensed to improve wakefulness and reduce EDS in adults with obstructive sleep apnoea (see separate RDTC evaluation).